James R. Anderson

James Robert Anderson KC (12 June 1864 – 7 April 1913) was a lawyer in the Colony and State of South Australia. He was unique in South Australia and possibly Australia in serving as Attorney General without being a Member of Parliament. Provided by Wikipedia
Showing 1 - 5 results of 5 for search 'James R. Anderson', query time: 0.02s Refine Results
  1. 1
    La mort naturelle d'une femelle chimpanzé âgée au sein de son groupe

    La mort naturelle d'une femelle chimpanzé âgée au sein de son groupe by James R Anderson

    Published 2015-03-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    La non-réciprocité d’un tiers induit la méfiance chez les singes capucins

    La non-réciprocité d’un tiers induit la méfiance chez les singes capucins by James R Anderson, Benoit Bucher, Margaux Levasseur, Kazuo Fujita

    Published 2016-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Exploring the roles of snoRNA-induced ribosome heterogeneity in equine osteoarthritis

    Exploring the roles of snoRNA-induced ribosome heterogeneity in equine osteoarthritis by Alzbeta Chabronova, Marie Walters, Sara Regårdh, Stine Jacobsen, Louise Bundgaard, James R. Anderson, Mandy J. Peffers

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

    TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia. by Mariana Maschietto, Richard D Williams, Tasnim Chagtai, Sergey D Popov, Neil J Sebire, Gordan Vujanic, Elizabeth Perlman, James R Anderson, Paul Grundy, Jeffrey S Dome, Kathy Pritchard-Jones

    Published 2014-01-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study.

    Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study. by Graham Cohen, Bernardo Rapoport, Sze W Chan, Paul Ruff, Ana Arance, Karmele Mujika Eizmendi, Baerin Houghton, Michael P Brown, Robert M Zielinski, Eva Muñoz Couselo, Megan Lyle, James R Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, Omobolaji Akala, Elliot Chartash, Conrad Jacobs

    Published 2024-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: